25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Lexaria Bioscience Corp
Buy, Hold or Sell?

Let's analyze Lexaria Bioscience Corp together

I guess you are interested in Lexaria Bioscience Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lexaria Bioscience Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Lexaria Bioscience Corp

I send you an email if I find something interesting about Lexaria Bioscience Corp.

1. Quick Overview

1.1. Quick analysis of Lexaria Bioscience Corp (30 sec.)










1.2. What can you expect buying and holding a share of Lexaria Bioscience Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$0.54
Expected worth in 1 year
$0.88
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$0.34
Return On Investment
21.4%

For what price can you sell your share?

Current Price per Share
$1.60
Expected price per share
$1.24 - $1.911
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Lexaria Bioscience Corp (5 min.)




Live pricePrice per Share (EOD)
$1.60
Intrinsic Value Per Share
$-6.52 - $-4.20
Total Value Per Share
$-5.99 - $-3.67

2.2. Growth of Lexaria Bioscience Corp (5 min.)




Is Lexaria Bioscience Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$9.3m$3.6m$4.5m55.3%

How much money is Lexaria Bioscience Corp making?

Current yearPrevious yearGrowGrow %
Making money-$1.8m-$1.5m-$307.8k-16.8%
Net Profit Margin-1,660.0%7,266.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Lexaria Bioscience Corp (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#613 / 925

Most Revenue
#641 / 925

Most Profit
#279 / 925

Most Efficient
#748 / 925
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Lexaria Bioscience Corp?

Welcome investor! Lexaria Bioscience Corp's management wants to use your money to grow the business. In return you get a share of Lexaria Bioscience Corp.

First you should know what it really means to hold a share of Lexaria Bioscience Corp. And how you can make/lose money.

Speculation

The Price per Share of Lexaria Bioscience Corp is $1.6. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lexaria Bioscience Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lexaria Bioscience Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.54. Based on the TTM, the Book Value Change Per Share is $0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lexaria Bioscience Corp.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.15-9.6%-0.10-6.5%-0.09-5.4%-0.08-5.2%-0.06-4.1%
Usd Book Value Change Per Share0.106.2%0.095.4%-0.04-2.3%0.021.2%0.010.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.000.0%0.000.0%
Usd Total Gains Per Share0.106.2%0.095.4%-0.03-2.2%0.021.2%0.010.7%
Usd Price Per Share2.08-3.33-1.58-2.80-1.72-
Price to Earnings Ratio-3.38--11.03--5.23--4.11--3.73-
Price-to-Total Gains Ratio21.04-7.24--9.96--22.47--21.62-
Price to Book Ratio3.89-7.43-7.35-6.46-6.24-
Price-to-Total Gains Ratio21.04-7.24--9.96--22.47--21.62-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.6
Number of shares625
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.090.02
Usd Total Gains Per Share0.090.02
Gains per Quarter (625 shares)53.6012.28
Gains per Year (625 shares)214.4049.14
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1021420414839
2042941829788
306436323145137
408588463193186
50107210604241235
60128612745290284
70150114886338333
80171517027386382
90193019168434431
100214421309483480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.039.00.02.5%5.071.00.06.6%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%7.013.00.035.0%14.026.00.035.0%25.049.02.032.9%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%1.00.075.01.3%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%7.013.00.035.0%14.026.00.035.0%25.049.02.032.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Lexaria Bioscience Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0990.086+15%-0.036+137%0.019+412%0.011+775%
Book Value Per Share--0.5350.469+14%0.210+155%0.391+37%0.247+117%
Current Ratio--29.63740.346-27%12.951+129%31.536-6%25.985+14%
Debt To Asset Ratio--0.0410.059-31%0.119-66%0.064-36%0.147-72%
Debt To Equity Ratio--0.0410.062-34%0.130-68%0.069-41%0.241-83%
Dividend Per Share----0%0.002-100%0.000-100%0.000-100%
Enterprise Value--44227819.00064966107.750-32%29844465.505+48%54260370.253-18%33345605.737+33%
Eps---0.154-0.104-32%-0.087-44%-0.084-45%-0.065-58%
Ev To Ebitda Ratio---4.109-12.288+199%-5.952+45%-8.584+109%-6.166+50%
Ev To Sales Ratio--60.117155.082-61%-232.343+486%190.884-69%156.658-62%
Free Cash Flow Per Share---0.155-0.095-39%-0.086-45%-0.071-54%-0.051-67%
Free Cash Flow To Equity Per Share--0.0920.088+5%-0.037+140%0.057+62%0.029+220%
Gross Profit Margin--1.0001.0010%1.0000%1.028-3%1.079-7%
Intrinsic Value_10Y_max---4.202--------
Intrinsic Value_10Y_min---6.521--------
Intrinsic Value_1Y_max---0.235--------
Intrinsic Value_1Y_min---0.393--------
Intrinsic Value_3Y_max---0.848--------
Intrinsic Value_3Y_min---1.414--------
Intrinsic Value_5Y_max---1.632--------
Intrinsic Value_5Y_min---2.682--------
Market Cap28084160.000-30%36509408.00058494039.500-38%27744956.005+32%49088566.553-26%30179413.862+21%
Net Profit Margin---14.700-16.600+13%72.668-120%-5.096-65%-23.266+58%
Operating Margin----12.8460%60.302-100%-8.2680%-18.1280%
Operating Ratio--15.63017.598-11%-59.570+481%9.432+66%26.484-41%
Pb Ratio2.990-30%3.8867.426-48%7.348-47%6.459-40%6.242-38%
Pe Ratio-2.597+23%-3.376-11.029+227%-5.229+55%-4.112+22%-3.729+10%
Price Per Share1.600-30%2.0803.333-38%1.581+32%2.797-26%1.719+21%
Price To Free Cash Flow Ratio-2.576+23%-3.348-11.931+256%-5.089+52%-10.461+212%-7.779+132%
Price To Total Gains Ratio16.187-30%21.0437.241+191%-9.959+147%-22.473+207%-21.624+203%
Quick Ratio--28.27938.651-27%12.285+130%30.573-8%24.139+17%
Return On Assets---0.276-0.201-27%-0.362+31%-0.252-9%-0.363+32%
Return On Equity---0.277-0.206-26%-0.381+38%-0.263-5%-0.442+60%
Total Gains Per Share--0.0990.086+15%-0.035+135%0.020+403%0.011+762%
Usd Book Value--9394056.0008237002.250+14%3681451.500+155%6864946.850+37%4337250.075+117%
Usd Book Value Change Per Share--0.0990.086+15%-0.036+137%0.019+412%0.011+775%
Usd Book Value Per Share--0.5350.469+14%0.210+155%0.391+37%0.247+117%
Usd Dividend Per Share----0%0.002-100%0.000-100%0.000-100%
Usd Enterprise Value--44227819.00064966107.750-32%29844465.505+48%54260370.253-18%33345605.737+33%
Usd Eps---0.154-0.104-32%-0.087-44%-0.084-45%-0.065-58%
Usd Free Cash Flow---2726045.000-1662993.500-39%-1500893.750-45%-1254602.100-54%-892083.750-67%
Usd Free Cash Flow Per Share---0.155-0.095-39%-0.086-45%-0.071-54%-0.051-67%
Usd Free Cash Flow To Equity Per Share--0.0920.088+5%-0.037+140%0.057+62%0.029+220%
Usd Market Cap28084160.000-30%36509408.00058494039.500-38%27744956.005+32%49088566.553-26%30179413.862+21%
Usd Price Per Share1.600-30%2.0803.333-38%1.581+32%2.797-26%1.719+21%
Usd Profit---2703699.000-1829930.250-32%-1522069.500-44%-1474347.800-45%-1140463.100-58%
Usd Revenue--183923.000124230.750+48%69002.500+167%108750.250+69%75301.075+144%
Usd Total Gains Per Share--0.0990.086+15%-0.035+135%0.020+403%0.011+762%
 EOD+2 -6MRQTTM+18 -19YOY+25 -145Y+16 -2310Y+26 -13

3.3 Fundamental Score

Let's check the fundamental score of Lexaria Bioscience Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.597
Price to Book Ratio (EOD)Between0-12.990
Net Profit Margin (MRQ)Greater than0-14.700
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than128.279
Current Ratio (MRQ)Greater than129.637
Debt to Asset Ratio (MRQ)Less than10.041
Debt to Equity Ratio (MRQ)Less than10.041
Return on Equity (MRQ)Greater than0.15-0.277
Return on Assets (MRQ)Greater than0.05-0.276
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Lexaria Bioscience Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.250
Ma 20Greater thanMa 501.763
Ma 50Greater thanMa 1002.048
Ma 100Greater thanMa 2002.325
OpenGreater thanClose1.560
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Lexaria Bioscience Corp

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Fundamental data was last updated by Penke on 2025-02-06 23:07:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Lexaria Bioscience Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lexaria Bioscience Corp to the Biotechnology industry mean.
  • A Net Profit Margin of -1,470.0% means that $-14.70 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lexaria Bioscience Corp:

  • The MRQ is -1,470.0%. The company is making a huge loss. -2
  • The TTM is -1,660.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,470.0%TTM-1,660.0%+190.0%
TTM-1,660.0%YOY7,266.8%-8,926.8%
TTM-1,660.0%5Y-509.6%-1,150.4%
5Y-509.6%10Y-2,326.6%+1,817.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,470.0%-100.3%-1,369.7%
TTM-1,660.0%-211.5%-1,448.5%
YOY7,266.8%-213.8%+7,480.6%
5Y-509.6%-346.2%-163.4%
10Y-2,326.6%-489.2%-1,837.4%
4.3.1.2. Return on Assets

Shows how efficient Lexaria Bioscience Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lexaria Bioscience Corp to the Biotechnology industry mean.
  • -27.6% Return on Assets means that Lexaria Bioscience Corp generated $-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lexaria Bioscience Corp:

  • The MRQ is -27.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.6%TTM-20.1%-7.5%
TTM-20.1%YOY-36.2%+16.1%
TTM-20.1%5Y-25.2%+5.1%
5Y-25.2%10Y-36.3%+11.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.6%-12.0%-15.6%
TTM-20.1%-12.1%-8.0%
YOY-36.2%-11.4%-24.8%
5Y-25.2%-12.8%-12.4%
10Y-36.3%-14.6%-21.7%
4.3.1.3. Return on Equity

Shows how efficient Lexaria Bioscience Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lexaria Bioscience Corp to the Biotechnology industry mean.
  • -27.7% Return on Equity means Lexaria Bioscience Corp generated $-0.28 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lexaria Bioscience Corp:

  • The MRQ is -27.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.7%TTM-20.6%-7.1%
TTM-20.6%YOY-38.1%+17.5%
TTM-20.6%5Y-26.3%+5.7%
5Y-26.3%10Y-44.2%+17.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.7%-15.4%-12.3%
TTM-20.6%-16.2%-4.4%
YOY-38.1%-14.7%-23.4%
5Y-26.3%-18.6%-7.7%
10Y-44.2%-19.5%-24.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Lexaria Bioscience Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Lexaria Bioscience Corp is operating .

  • Measures how much profit Lexaria Bioscience Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lexaria Bioscience Corp to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lexaria Bioscience Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,284.6%+1,284.6%
TTM-1,284.6%YOY6,030.2%-7,314.8%
TTM-1,284.6%5Y-826.8%-457.8%
5Y-826.8%10Y-1,812.8%+985.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--201.5%+201.5%
TTM-1,284.6%-313.4%-971.2%
YOY6,030.2%-215.2%+6,245.4%
5Y-826.8%-371.8%-455.0%
10Y-1,812.8%-492.1%-1,320.7%
4.3.2.2. Operating Ratio

Measures how efficient Lexaria Bioscience Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 15.63 means that the operating costs are $15.63 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 15.630. The company is inefficient in keeping operating costs low. -1
  • The TTM is 17.598. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ15.630TTM17.598-1.968
TTM17.598YOY-59.570+77.168
TTM17.5985Y9.432+8.166
5Y9.43210Y26.484-17.052
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.6302.139+13.491
TTM17.5983.198+14.400
YOY-59.5703.358-62.928
5Y9.4324.842+4.590
10Y26.4846.500+19.984
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Lexaria Bioscience Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Lexaria Bioscience Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 29.64 means the company has $29.64 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 29.637. The company is very able to pay all its short-term debts. +2
  • The TTM is 40.346. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ29.637TTM40.346-10.709
TTM40.346YOY12.951+27.395
TTM40.3465Y31.536+8.810
5Y31.53610Y25.985+5.551
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ29.6373.610+26.027
TTM40.3463.871+36.475
YOY12.9514.609+8.342
5Y31.5365.977+25.559
10Y25.9856.216+19.769
4.4.3.2. Quick Ratio

Measures if Lexaria Bioscience Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lexaria Bioscience Corp to the Biotechnology industry mean.
  • A Quick Ratio of 28.28 means the company can pay off $28.28 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 28.279. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 38.651. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ28.279TTM38.651-10.372
TTM38.651YOY12.285+26.366
TTM38.6515Y30.573+8.078
5Y30.57310Y24.139+6.435
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.2793.085+25.194
TTM38.6513.360+35.291
YOY12.2854.400+7.885
5Y30.5735.972+24.601
10Y24.1396.483+17.656
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Lexaria Bioscience Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Lexaria Bioscience Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lexaria Bioscience Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Lexaria Bioscience Corp assets are financed with 4.1% credit (debt) and the remaining percentage (100% - 4.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 0.041. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.059. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.041TTM0.059-0.018
TTM0.059YOY0.119-0.060
TTM0.0595Y0.064-0.005
5Y0.06410Y0.147-0.083
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0410.341-0.300
TTM0.0590.343-0.284
YOY0.1190.315-0.196
5Y0.0640.363-0.299
10Y0.1470.384-0.237
4.5.4.2. Debt to Equity Ratio

Measures if Lexaria Bioscience Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lexaria Bioscience Corp to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.1% means that company has $0.04 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lexaria Bioscience Corp:

  • The MRQ is 0.041. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.062. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.041TTM0.062-0.021
TTM0.062YOY0.130-0.067
TTM0.0625Y0.069-0.007
5Y0.06910Y0.241-0.172
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0410.386-0.345
TTM0.0620.429-0.367
YOY0.1300.391-0.261
5Y0.0690.450-0.381
10Y0.2410.495-0.254
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lexaria Bioscience Corp generates.

  • Above 15 is considered overpriced but always compare Lexaria Bioscience Corp to the Biotechnology industry mean.
  • A PE ratio of -3.38 means the investor is paying $-3.38 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lexaria Bioscience Corp:

  • The EOD is -2.597. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.376. Based on the earnings, the company is expensive. -2
  • The TTM is -11.029. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.597MRQ-3.376+0.779
MRQ-3.376TTM-11.029+7.653
TTM-11.029YOY-5.229-5.800
TTM-11.0295Y-4.112-6.918
5Y-4.11210Y-3.729-0.383
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.597-2.247-0.350
MRQ-3.376-2.706-0.670
TTM-11.029-3.253-7.776
YOY-5.229-3.392-1.837
5Y-4.112-6.132+2.020
10Y-3.729-6.735+3.006
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lexaria Bioscience Corp:

  • The EOD is -2.576. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.348. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.931. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.576MRQ-3.348+0.773
MRQ-3.348TTM-11.931+8.583
TTM-11.931YOY-5.089-6.842
TTM-11.9315Y-10.461-1.470
5Y-10.46110Y-7.779-2.682
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.576-3.026+0.450
MRQ-3.348-3.582+0.234
TTM-11.931-3.816-8.115
YOY-5.089-4.463-0.626
5Y-10.461-8.265-2.196
10Y-7.779-9.266+1.487
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Lexaria Bioscience Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.89 means the investor is paying $3.89 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lexaria Bioscience Corp:

  • The EOD is 2.990. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.886. Based on the equity, the company is fair priced.
  • The TTM is 7.426. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.990MRQ3.886-0.897
MRQ3.886TTM7.426-3.539
TTM7.426YOY7.348+0.078
TTM7.4265Y6.459+0.967
5Y6.45910Y6.242+0.217
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.9901.948+1.042
MRQ3.8862.223+1.663
TTM7.4262.427+4.999
YOY7.3482.469+4.879
5Y6.4593.767+2.692
10Y6.2424.507+1.735
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lexaria Bioscience Corp.

4.8.1. Institutions holding Lexaria Bioscience Corp

Institutions are holding 6.08% of the shares of Lexaria Bioscience Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Invenomic Capital Management, LP2.71060.0797475773-37800-7.3602
2024-09-30Geode Capital Management, LLC0.856801503913560831.022
2024-09-30Vanguard Group Inc0.621101090221543616.4939
2024-09-30GenTrust, LLC0.34180.0096000000
2024-09-30Raymond James Finl Svs Advisors, Inc.0.25580.000244900-3900-7.9918
2024-09-30State Street Corp0.223903930100
2024-09-30BlackRock Inc0.156402744500
2024-09-30Morgan Stanley - Brokerage Accounts0.1309022982-22982-50
2024-09-30XTX Topco Ltd0.10610.004118626602447.8019
2024-09-30Northern Trust Corp0.104801838900
2024-09-30Bank of Montreal0.0798014000140000
2024-09-30BMO Capital Markets Corp.0.0798014000140000
2024-12-31Wealth Enhancement Advisory Services, LLC0.07880.00011382300
2024-09-30HighTower Advisors, LLC0.07420.000113023130230
2024-12-31Byrne Asset Management LLC0.07410.0192130007400132.1429
2024-09-30HRT FINANCIAL LLC0.05840.000210257102570
2024-09-30Royal Bank of Canada0.04150728300
2024-12-31Oakworth Capital Inc0.02850.0007500000
2024-09-30Wells Fargo & Co0.014202500-800-24.2424
2024-09-30Advisor Group Holdings, Inc.0.0130229000
Total 6.05050.11331062005+50266+4.7%

4.9.2. Funds holding Lexaria Bioscience Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Invenomic Institutional1.14310.0438200648-62769-23.8288
2024-12-31Vanguard Institutional Extnd Mkt Idx Tr0.66790.000211722900
2024-12-31Fidelity Extended Market Index0.50470.000588586858810.7353
2024-12-31Fidelity Total Market Index0.15020.00012636800
2024-12-31Extended Equity Market Fund K0.1270.000322298-307-1.3581
2024-12-31Fidelity Series Total Market Index0.10620.000118639-493-2.5768
2024-12-31Spartan Extended Market Index Pool E0.08640.000515174537854.9
2024-12-31Northern Trust Extended Eq Market Idx0.06980.00031224900
2024-12-31NT Ext Equity Mkt Idx Fd - L0.06980.00031224900
2024-12-31Fidelity Nasdaq Composite Index0.06620.000111622270630.3499
2024-12-31Vanguard U.S. Eq Idx £ Acc0.05810.00011020400
2024-12-31Spartan Total Market Index Pool E0.03530619500
2024-12-31NT Ext Equity Mkt Idx Fd - NL0.03160.0002554700
2024-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02510.00024397-73-1.6331
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.01660.0003291929190
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.01660.0003291929190
2024-12-31Extended Equity Market Fund M0.01650.00032896280.9763
2024-12-31State St US Extended Mkt Indx NL Cl C0.01140.0002200000
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.01080.0005189030.159
2024-06-30SSgA U.S. Total Market Index Strategy0.0047082024342.1144
Total 3.2180.0483564849-40858-7.2%

5.3. Insider Transactions

Insiders are holding 7.03% of the shares of Lexaria Bioscience Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-12-02Richard ChristopherBUY228282.24
2024-08-12Catherine C TurkelBUY16003.13
2024-07-31Vanessa CarleSELL25674
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-11-30. Currency in USD. All numbers in thousands.

Summary
Total Assets9,794
Total Liabilities400
Total Stockholder Equity9,774
 As reported
Total Liabilities 400
Total Stockholder Equity+ 9,774
Total Assets = 9,794

Assets

Total Assets9,794
Total Current Assets8,826
Long-term Assets968
Total Current Assets
Cash And Cash Equivalents 8,078
Short-term Investments 40
Net Receivables 263
Other Current Assets 444
Total Current Assets  (as reported)8,826
Total Current Assets  (calculated)8,826
+/-0
Long-term Assets
Property Plant Equipment 399
Intangible Assets 505
Long-term Assets Other 64
Long-term Assets  (as reported)968
Long-term Assets  (calculated)968
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities298
Long-term Liabilities102
Total Stockholder Equity9,774
Total Current Liabilities
Short-term Debt 29
Accounts payable 262
Other Current Liabilities 269
Total Current Liabilities  (as reported)298
Total Current Liabilities  (calculated)560
+/- 262
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt102
Long-term Liabilities  (as reported)102
Long-term Liabilities  (calculated)102
+/-0
Total Stockholder Equity
Retained Earnings -54,262
Accumulated Other Comprehensive Income -23
Other Stockholders Equity 64,060
Total Stockholder Equity (as reported)9,774
Total Stockholder Equity (calculated)9,774
+/-0
Other
Capital Stock17
Cash and Short Term Investments 8,118
Common Stock Shares Outstanding 16,669
Liabilities and Stockholders Equity 9,794
Net Debt -7,948
Net Invested Capital 9,774
Net Working Capital 8,528
Property Plant and Equipment Gross 925
Short Long Term Debt Total 131



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-11-302024-08-312024-05-312024-02-292023-11-302023-08-312023-05-312023-02-282022-11-302022-08-312022-05-312022-02-282021-11-302021-08-312021-05-312021-02-282020-11-302020-08-312020-05-312020-02-292019-11-302019-08-312019-05-312019-02-282018-11-302018-08-312018-05-312018-02-282017-11-302017-08-312017-05-312017-02-282016-11-302016-08-312016-05-312016-02-292015-11-302015-08-312015-05-312015-02-282014-11-302014-08-312014-05-312014-02-282013-11-302013-08-312013-05-312013-02-282012-11-302012-08-312012-05-312012-02-292011-11-302011-08-312011-05-312011-02-282010-11-302010-08-312010-05-312010-02-282009-11-302009-08-312009-05-312009-02-282008-11-302008-05-312008-02-292007-11-302007-08-312007-05-312007-02-282006-11-302006-08-312006-05-312006-02-282005-11-30
> Total Assets 
1,192
1,164
1,114
1,114
2,719
2,475
2,439
3,191
3,796
4,236
3,600
3,763
3,390
3,250
3,250
3,329
3,398
3,339
3,418
3,278
3,717
3,513
3,865
4,339
4,228
4,131
4,224
4,192
3,923
3,799
3,683
3,573
3,560
4,838
4,566
2,251
1,211
1,199
712
496
389
331
567
1,137
869
3,144
2,860
2,497
2,841
2,709
2,432
3,544
4,274
3,457
2,675
2,746
1,986
3,320
2,828
2,174
12,172
10,548
13,267
11,746
11,415
9,138
7,834
6,213
4,855
5,240
3,084
3,627
6,352
10,018
8,868
9,794
9,7948,86810,0186,3523,6273,0845,2404,8556,2137,8349,13811,41511,74613,26710,54812,1722,1742,8283,3201,9862,7462,6753,4574,2743,5442,4322,7092,8412,4972,8603,1448691,1375673313894967121,1991,2112,2514,5664,8383,5603,5733,6833,7993,9234,1924,2244,1314,2284,3393,8653,5133,7173,2783,4183,3393,3983,3293,2503,2503,3903,7633,6004,2363,7963,1912,4392,4752,7191,1141,1141,1641,192
   > Total Current Assets 
216
114
7
7
1,299
438
47
983
134
359
213
691
411
331
331
372
478
443
493
140
464
304
730
264
323
265
517
473
285
216
182
146
165
1,467
1,201
2,198
1,158
1,158
675
456
337
279
510
1,067
804
3,079
2,795
2,417
2,745
2,587
2,284
3,231
3,641
2,608
1,819
1,911
1,180
2,528
1,926
1,308
10,946
9,686
12,443
10,901
10,572
8,291
6,978
5,359
4,004
4,235
2,200
2,694
5,417
9,093
7,898
8,826
8,8267,8989,0935,4172,6942,2004,2354,0045,3596,9788,29110,57210,90112,4439,68610,9461,3081,9262,5281,1801,9111,8192,6083,6413,2312,2842,5872,7452,4172,7953,0798041,0675102793374566751,1581,1582,1981,2011,467165146182216285473517265323264730304464140493443478372331331411691213359134983474381,29977114216
       Cash And Cash Equivalents 
210
114
7
7
1,285
427
29
920
78
102
50
670
365
240
240
330
446
416
431
63
280
127
494
31
140
121
16
181
39
45
28
66
29
952
578
431
792
832
260
84
40
37
93
124
524
2,789
2,533
2,210
2,318
2,063
1,727
2,645
3,093
1,996
1,285
1,333
740
2,034
1,294
525
9,347
8,109
10,918
9,682
8,359
7,051
5,813
4,533
3,272
3,164
1,352
1,954
4,705
8,459
6,500
8,078
8,0786,5008,4594,7051,9541,3523,1643,2724,5335,8137,0518,3599,68210,9188,1099,3475251,2942,0347401,3331,2851,9963,0932,6451,7272,0632,3182,2102,5332,7895241249337408426083279243157895229662845391811612114031494127280634314164463302402403656705010278920294271,28577114210
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
10
71
71
75
64
23
24
18
19
44
471
401
834
493
552
288
347
270
268
270
126
72
88
46
56
40
405646887212627026827034728855249383440147144191824236475717110180000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
13
5
10
35
38
243
161
16
42
91
91
42
22
20
57
75
176
170
232
231
176
140
498
291
240
167
152
79
131
100
99
75
35
22
31
35
44
15
131
649
24
57
45
72
188
268
266
215
219
226
273
326
227
254
314
427
628
954
342
462
507
155
202
286
137
172
175
535
357
208
84
263
26384208357535175172137286202155507462342954628427314254227326273226219215266268188724557246491311544353122357599100131791521672402914981401762312321701767557202242919142161612433835105130000
       Other Current Assets 
6
0
0
0
0
6
7
29
18
14
3
6
4
0
0
0
9
7
5
2
9
6
4
2
6
4
3
1
6
4
3
2
5
415
524
1,673
253
225
215
149
112
101
151
143
113
0
150
58
177
162
194
183
149
123
69
96
65
89
182
185
364
0
319
237
0
757
577
260
587
630
547
132
267
380
1,188
444
4441,18838026713254763058726057775702373190364185182896596691231491831941621775815001131431511011121492152252531,673524415523461346246925790004631418297600006
   > Long-term Assets 
976
1,050
1,107
1,107
1,420
2,037
2,393
2,207
3,662
3,878
3,386
3,072
2,979
2,920
2,920
2,957
2,921
2,896
2,925
3,138
3,252
3,210
3,135
4,075
3,906
3,867
3,707
3,719
3,638
3,583
3,501
3,427
3,395
3,371
3,366
53
53
41
37
40
52
52
56
70
65
65
65
80
96
122
148
313
633
849
856
835
806
792
902
867
1,226
862
824
845
842
846
856
854
851
1,004
884
933
935
925
970
968
9689709259359338841,0048518548568468428458248621,22686790279280683585684963331314812296806565657056525240374153533,3663,3713,3953,4273,5013,5833,6383,7193,7073,8673,9064,0753,1353,2103,2523,1382,9252,8962,9212,9572,9202,9202,9793,0723,3863,8783,6622,2072,3932,0371,4201,1071,1071,050976
       Property Plant Equipment 
976
1,050
1,107
1,107
1,420
2,037
2,393
2,207
3,662
3,878
3,386
3,072
2,979
2,920
2,920
2,957
2,921
2,896
2,925
3,138
3,252
3,210
3,135
4,042
3,857
3,818
3,707
3,719
3,638
3,583
3,501
3,427
3,395
3,371
3,322
0
0
0
0
3
3
3
2
2
2
2
2
2
2
1
1
123
433
607
591
565
538
511
610
571
533
496
459
466
431
406
368
354
333
455
422
390
376
363
390
399
39939036337639042245533335436840643146645949653357161051153856559160743312311222222233300003,3223,3713,3953,4273,5013,5833,6383,7193,7073,8183,8574,0423,1353,2103,2523,1382,9252,8962,9212,9572,9202,9202,9793,0723,3863,8783,6622,2072,3932,0371,4201,1071,1071,050976
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41
37
37
49
49
54
67
63
63
63
78
94
121
147
190
200
243
265
269
268
281
292
296
299
366
365
379
411
441
488
501
518
549
463
494
519
499
517
505
5055174995194944635495185014884414113793653662992962922812682692652432001901471219478636363675449493737410000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
394
0
0
0
0
0
0
0
0
92
0
0
0
0
0
0
0000009200000000394000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
27
28
24
24
2,015
21
99
514
401
886
761
1,001
791
788
788
1,032
1,061
1,165
1,213
1,125
1,649
1,580
1,476
1,678
1,676
1,811
1,836
1,771
1,614
1,538
1,458
1,474
1,533
1,105
1,017
789
38
63
55
177
284
377
479
514
379
85
92
96
69
72
44
130
500
132
185
130
63
120
346
353
470
281
203
277
195
225
201
282
223
1,198
404
254
204
271
1,209
400
4001,2092712042544041,198223282201225195277203281470353346120631301851325001304472699692853795144793772841775563387891,0171,1051,5331,4741,4581,5381,6141,7711,8361,8111,6761,6781,4761,5801,6491,1251,2131,1651,0611,0327887887911,00176188640151499212,01524242827
   > Total Current Liabilities 
27
28
24
24
2,015
21
99
514
401
886
761
277
19
26
26
1,032
1,061
1,090
1,138
1,050
973
981
877
1,079
1,676
1,811
1,836
1,711
1,555
1,478
1,399
1,415
1,473
1,046
957
789
38
63
55
177
284
332
434
469
334
40
92
96
69
72
44
130
500
132
185
130
63
91
226
242
399
221
153
238
166
207
194
282
223
1,056
268
125
82
156
1,099
298
2981,099156821252681,05622328219420716623815322139924222691631301851325001304472699692403344694343322841775563387899571,0461,4731,4151,3991,4781,5551,7111,8361,8111,6761,0798779819731,0501,1381,0901,0611,03226261927776188640151499212,01524242827
       Short-term Debt 
0
0
0
0
1,987
0
50
506
50
731
722
273
3
13
13
789
801
847
822
910
804
878
783
755
1,553
1,612
1,652
1,643
1,476
1,384
1,299
1,277
1,285
910
806
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
36
37
45
46
47
48
49
50
43
40
29
32
28
26
53
27
28
29
2928275326283229404350494847464537361200000000000000000000008069101,2851,2771,2991,3841,4761,6431,6521,6121,55375578387880491082284780178913133273722731505065001,9870000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
8
8
8
0
0
0
0
0
0
0
0
0
0
0000000000888888000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
27
28
0
19
2
0
22
4
19
120
21
3
0
0
0
0
0
0
0
0
167
101
92
322
122
197
182
67
77
92
98
136
186
134
150
109
36
61
33
70
46
66
90
74
26
13
33
60
63
63
36
108
26
87
31
89
56
43
45
13
135
164
55
173
61
90
57
231
180
1,011
225
92
48
121
1,058
262
2621,05812148922251,01118023157906117355164135134543568931872610836636360331326749066467033613610915013418613698927767182197122322921011670000000032112019422021902827
       Other Current Liabilities 
0
0
0
5
13
20
24
5
321
13
18
2
16
0
13
243
260
243
316
139
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
680
2
2
22
108
238
257
331
373
283
7
43
25
6
9
8
22
430
45
153
41
8
30
101
158
219
6
6
8
56
67
94
11
10
13
15
7
-26
7
0
269
26907-26715131011946756866219158101308411534543022896254372833733312572381082222680222222222222222139316243260243130162181332152420135000
   > Long-term Liabilities 
27
28
0
19
1,988
0
72
510
69
851
743
724
772
763
763
789
801
75
75
75
676
599
599
599
1,675
1,809
1,834
59
59
59
59
59
59
59
59
109
36
61
33
70
46
45
45
45
45
45
50
71
63
63
36
108
70
87
73
93
56
29
120
111
70
60
50
40
29
18
7
271
213
143
136
130
122
115
109
102
102109115122130136143213271718294050607011112029569373877010836636371504545454545467033613610959595959595959591,8341,8091,675599599599676757575801789763763772724743851695107201,9881902827
> Total Stockholder Equity
1,165
1,135
0
1,090
705
2,455
2,340
2,676
3,395
3,351
2,839
2,762
2,599
0
2,462
2,298
2,337
2,175
2,205
2,154
2,068
1,933
2,389
2,661
2,552
2,320
2,388
2,421
2,309
2,262
2,225
2,099
2,027
3,733
3,550
1,416
1,145
1,152
772
464
265
121
266
807
691
3,265
3,006
2,402
2,772
2,637
2,388
3,414
2,779
3,179
2,383
2,526
1,880
3,187
2,525
1,878
11,771
10,344
13,266
11,681
11,455
9,183
7,949
6,262
4,974
4,395
3,044
3,742
6,521
10,123
8,036
9,774
9,7748,03610,1236,5213,7423,0444,3954,9746,2627,9499,18311,45511,68113,26610,34411,7711,8782,5253,1871,8802,5262,3833,1792,7793,4142,3882,6372,7722,4023,0063,2656918072661212654647721,1521,1451,4163,5503,7332,0272,0992,2252,2622,3092,4212,3882,3202,5522,6612,3891,9332,0682,1542,2052,1752,3372,2982,46202,5992,7622,8393,3513,3952,6762,3402,4557051,09001,1351,165
   Common Stock
18
18
0
18
18
22
22
24
24
24
24
24
24
0
11
11
12
12
13
13
13
13
16
16
16
16
16
16
16
16
16
16
17
32
33
34
35
40
40
40
45
46
51
55
56
67
68
69
71
72
76
77
78
78
79
81
81
90
90
3
5
5
6
6
6
6
6
6
6
8
8
10
12
16
16
0
01616121088666666655390908181797878777672716968675655514645404040353433321716161616161616161616131313131212111102424242424242222181801818
   Retained Earnings -54,262-51,559-49,374-47,592-46,943-45,763-44,524-42,153-40,854-39,099-37,631-35,248-33,822-31,829-30,651-28,094-28,498-27,802-27,087-25,726-24,776-23,868-22,790-21,618-20,470-19,769-18,552-15,127-13,749-13,170-12,483-12,144-11,696-11,301-10,986-10,728-10,468-10,086-9,570-9,103-8,663-6,229-5,653-5,160-5,058-4,931-4,874-4,826-4,714-4,746-4,814-4,582-4,463-4,463-4,210-4,055-3,924-3,847-3,817-3,655-3,372-3,203-3,203-2,781-2,618-2,239-1,706-1,640-2,348-1,208-837-584-180-180-135-105
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
1,252
1,252
0
1,252
1,271
3,270
3,527
5,000
5,011
5,033
5,054
5,356
5,356
0
5,654
5,659
5,980
5,980
6,039
6,065
6,110
6,131
6,836
7,108
7,117
7,117
7,117
7,119
7,119
7,119
7,140
7,140
7,170
9,354
9,746
10,044
10,213
10,683
10,818
10,892
10,949
11,061
11,515
12,448
12,779
15,681
16,108
16,081
17,828
21,124
22,096
23,807
24,319
25,891
26,172
27,221
27,525
30,323
30,237
30,373
39,860
40,990
45,089
45,498
46,697
46,809
47,041
47,110
47,121
48,912
48,799
50,671
54,121
59,503
59,599
64,060
64,06059,59959,50354,12150,67148,79948,91247,12147,11047,04146,80946,69745,49845,08940,99039,86030,37330,23730,32327,52527,22126,17225,89124,31923,80722,09621,12417,82816,08116,10815,68112,77912,44811,51511,06110,94910,89210,81810,68310,21310,0449,7469,3547,1707,1407,1407,1197,1197,1197,1177,1177,1177,1086,8366,1316,1106,0656,0395,9805,9805,6595,65405,3565,3565,0545,0335,0115,0003,5273,2701,2711,25201,2521,252



5.3. Balance Sheets

Currency in USD. All numbers in thousands.